Loading patent…
AssigneeSuzhou Institute of Systems Medicine
InventorsYili Yang, Long Cui, Tingyu Wu
Estimating the term…
The invention provides a pharmaceutical composition and a method for treating cancer, and the composition comprises a proteasome inhibitor and a nuclear export inhibitor. The composition has synergistic effects on treating cancers, particularly a solid tumor cancer. Specifically, the proteasome inhibitor bortezomib and CRM1 inhibitor KPT330 induce apoptosis and cell cycle arrest in sensitive cells, such as HCT116 and RKO cells. Bortezomib induces the nuclear export of p53, whereas it could be effectively blocked by KPT330. CRM1 inhibitor KPT330 synergistically sensitizes CRC cells to bortezomib treatment in vitro and in vivo, through inhibiting nuclear export and restoring functions of p53. The invention also provides use of proteasome inhibitor in a solid tumor cancer. The invention provides a rationale for the use of proteasome inhibitor together with nuclear export blocker in the treatment of cancers, such as colorectal cancer.
A pharmaceutical composition for treating colorectal cancer, comprising
A method for treating colorectal cancer, comprising administrating to a subject in need thereof a pharmaceutical composition comprising a proteasome inhibitor or a pharmaceutically acceptable salt, solvate, hydrate, cocrystal or prodrug thereof, and a nuclear export inhibitor or a pharmaceutically acceptable salt, solvate, hydrate, cocrystal or prodrug thereof, as an active agent,
A method for treating colorectal cancer, comprising simultaneously administering to a subject with a proteasome inhibitor and a nuclear export inhibitor,
Dependencies are inferred from the claim text.